Published in Vaccine Weekly, September 8th, 2004
According to recent research from Canada, "We have previously described a novel family of immunomodulatory synthetic oligonucleotides characterized by a phosphodiester backbone, a length of six bases and a 5'G3 xG2 3' sequence, where x is A, C, G or T. In the present study, we have evaluated whether these 5G3 xG2 3' oligonucleotides possess additional activities essential for adequate cancer vaccination. Immunization for the treatment of cancer requires an adjuvant, a source of tumor-associated antigen (s), for...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly